Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Guided Therapeutics (GTHP) Other Non-Current Liabilities (2016 - 2025)

Guided Therapeutics' Other Non-Current Liabilities history spans 12 years, with the latest figure at $79000.0 for Q3 2025.

  • For Q3 2025, Other Non-Current Liabilities rose 295.0% year-over-year to $79000.0; the TTM value through Sep 2025 reached $79000.0, up 295.0%, while the annual FY2024 figure was $118000.0, N/A changed from the prior year.
  • Other Non-Current Liabilities for Q3 2025 was $79000.0 at Guided Therapeutics, up from $60000.0 in the prior quarter.
  • Across five years, Other Non-Current Liabilities topped out at $118000.0 in Q4 2024 and bottomed at -$38000.0 in Q3 2021.
  • The 4-year median for Other Non-Current Liabilities is $24500.0 (2021), against an average of $34833.3.
  • The largest annual shift saw Other Non-Current Liabilities crashed 205.56% in 2021 before it soared 361.54% in 2025.
  • A 4-year view of Other Non-Current Liabilities shows it stood at -$32000.0 in 2021, then soared by 84.38% to -$5000.0 in 2022, then surged by 2460.0% to $118000.0 in 2024, then crashed by 33.05% to $79000.0 in 2025.
  • Per Business Quant, the three most recent readings for GTHP's Other Non-Current Liabilities are $79000.0 (Q3 2025), $60000.0 (Q2 2025), and $66000.0 (Q1 2025).